GSK, Sanofi Shares Brighten As Thousands Of Zantac Lawsuits Are Dismissed
LONDON/PARIS (Reuters) – Shares of GSK and Sanofi surged in early trading on Wednesday, following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer. The ruling on Tuesday by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocked out about 50,000 claims in federal court, although it…
